RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia

Leukemias are routinely sub-typed for risk/outcome prediction and therapy choice using acquired mutations and chromosomal rearrangements. Down syndrome acute lymphoblastic leukemia (DS‐ALL) is characterized by high frequency of CRLF2‐rearrangements, JAK2‐mutations, or RAS‐pathway mutations. Intrigui...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncogene
Main Authors: Koschut, David, Ray, Debleena, Li, Zhenhua, Giarin, Emanuela, Groet, Jürgen, Alić, Ivan, Kham, Shirley Kow-Yin, Chng, Wee Joo, Ariffin, Hany, Weinstock, David M., Yeoh, Allen Eng-Juh, Basso, Giuseppe, Nižetić, Dean
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7843419/
https://ncbi.nlm.nih.gov/pubmed/33247204
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-020-01567-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados